Federal Register / Vol. 87, No. 115 / Wednesday, June 15, 2022 / Notices 36129 

foster bi-directional learning among the 

participating organizations, to check site 

progress during the implementation 

period and to understand ‘‘real-time’’ 

challenges, successes, and lessons 

learned. Standard questions for each 

ECHO session will be asked to foster 

shared learning and discussion. AHRQ 

will use the information collected to 

assess and enhance the feasibility of 

organizations in adopting the Resource 

to stimulate diagnostic safety 

measurement activities for learning and 

improvement. AHRQ’s ability to 

publicly share a diagnostic 

measurement resource that has been 

scientifically validated is expected to be 

of great interest to the health care 

community and important in helping 

organizations measure diagnostic safety 

for patient safety and quality 

improvement efforts. 

Estimated Annual Respondent Burden 

EXHIBIT 1—ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Hours per 

response 

Total burden 

hours 

Organizational Characteristics Survey ............................................................. 10 1 1 10 

Organizational Self-Assessment (from Measure Dx) ...................................... 10 1 .5 5 

Safer Dx Checklist ........................................................................................... 10 2 0.25 5 

Pre-Test Interview Protocol ............................................................................. 20 1 1 20 

Post-test Evaluation Interview Protocol ........................................................... 20 1 1 20 

Team Questionnaire ........................................................................................ 10 2 0.25 5 

Case Review Summary Form .......................................................................... 10 2 .75 15 

ECHO Call Protocol ......................................................................................... 10 6 1 60 

Total .......................................................................................................... 100 NA NA 140 

EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN

Form name Number of 

respondents 

Total burden 

hours 

Average 

hourly wage 

rate * 

Total cost 

burden 

Organizational Characteristics Survey ............................................................. 10 10 a $57.61 $576.1 

Organizational Self-Assessment (from Measure Dx) ...................................... 10 5 a 57.61 288.05 

Safer Dx Checklist ........................................................................................... 10 5 a 57.61 288.05 

Pre-Test Interview Protocol ............................................................................. 20 20 b 136.37 2,727.40 

Post-test Evaluation Interview Protocol ........................................................... 20 20 b 136.37 2,727.40 

Team Questionnaire ........................................................................................ 10 5 a 57.61 288.05 

Case Review Summary Form .......................................................................... 10 15 b 136.37 2,045.60 

ECHO Call Protocol ......................................................................................... 10 60 a 57.61 3,456.60 

Total .......................................................................................................... 100 140 NA 12,397.25 

* National Compensation Survey: Occupational wages in the United States May 2021 ‘‘U.S. Department of Labor, Bureau of Labor Statistics.’’ 

(https://www.bls.gov/oes/current/oes_nat.htm#29-0000). aBased on the mean wages for Medical and Health Services Managers (Code 11–9111). bBased on the mean wages for Physicians (broad) (Code 29–1210). 

Request for Comments 

In accordance with the Paperwork 

Reduction Act, 44 U.S.C. 3501–3520, 

comments on AHRQ’s information 

collection are requested with regard to 

any of the following: (a) whether the 

proposed collection of information is 

necessary for the proper performance of 

AHRQ’s health care research and health 

care information dissemination 

functions, including whether the 

information will have practical utility; 

(b) the accuracy of AHRQ’s estimate of 

burden (including hours and costs) of 

the proposed collection(s) of 

information; (c) ways to enhance the 

quality, utility and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information upon the 

respondents, including the use of 

automated collection techniques or 

other forms of information technology. 

Comments submitted in response to 

this notice will be summarized and 

included in the Agency’s subsequent 

request for OMB approval of the 

proposed information collection. All 

comments will become a matter of 

public record. 

Dated: June 9, 2022. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2022–12828 Filed 6–14–22; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Rescinding Requirement for Negative 

Pre-Departure COVID–19 Test Result 

or Documentation of Recovery From 

COVID–19 for All Airline or Other 

Aircraft Passengers Arriving Into the 

United States From Any Foreign 

Country 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), is hereby 

rescinding the Order titled, 


jspears on DSK121TN23PROD with NOTICES1
36130 Federal Register / Vol. 87, No. 115 / Wednesday, June 15, 2022 / Notices 

1The Order stems from previous testing 

requirements, which varied in scope and 

applicability. For example, on December 27, 2020, 

the CDC implemented the Order, Requirement for 

Negative Pre-Departure COVID–19 Test Result for 

All Airline Passengers Arriving Into the United 

States From the United Kingdom, in response to the 

Alpha variant and rising number of COVID–19 

cases. 

2This new framework examines three currently 

relevant metrics for each U.S. county: new COVID– 

19 hospital admissions per 100,000 population in 

the past seven days, the percent of staffed inpatient 

beds occupied by patients with COVID–19, and 

total new COVID–19 cases per 100,000 population 

in the past seven days. Indicators for Monitoring 

COVID–19 Community Levels and Implementing 

Prevention Strategies, Centers for Disease Control 

and Prevention, https://www.cdc.gov/coronavirus/ 

2019-ncov/downloads/science/Scientific-Rationalesummary_COVID-19-Community-Levels_

2022.02.23.pptx (Feb. 25, 2022). 

‘‘Requirement for Negative PreDeparture COVID–19 Test Result or 

Documentation of Recovery from 

COVID–19 for All Airline or Other 

Aircraft Passengers Arriving Into the 

United States From Any Foreign 

Country.’’ As subsequently amended, 

the Order required all air passengers, 

two years or older, traveling to the 

United States from a foreign country to 

present a negative COVID–19 test result 

from a sample taken no more than one 

day before departure, or documentation 

of recovery from COVID–19 in the past 

90 days, before boarding a flight. 

DATES: This rescission was implemented 

June 12, 2022. 

FOR FURTHER INFORMATION CONTACT: 

Candice Swartwood, Division of Global 

Migration and Quarantine, National 

Center for Emerging and Zoonotic 

Infectious Diseases, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, MS H16–4, Atlanta, GA 

30329; Telephone: 404–498–1600; 

Email: dgmqpolicyoffice@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Background 

The Order was one of several actions 

taken by the Federal government during 

earlier phases of the COVID–19 

pandemic to help mitigate the further 

transmission and spread of SARS–CoV– 

2 variants into and within the United 

States. Since then, many circumstances 

have changed, including the widespread 

uptake of effective COVID–19 vaccines 

and accompanying vaccine- and 

infection-induced immunity, as well as 

the availability of effective therapeutics, 

and CDC remains focused on preventing 

medically significant disease, 

hospitalizations, and deaths from 

COVID–19. Accordingly, CDC has 

determined that it is not currently 

necessary to leave the Order in place to 

prevent introduction of currently 

circulating SARS–CoV–2 variants into 

the United States. 

CDC continues to recommend that all 

travelers remain up to date with 

vaccination against COVID–19 and get 

tested for current infection with a viral 

test before and after they travel, and 

after any known exposure to a person 

with COVID–19, so they can take 

appropriate precautions to reduce the 

risk of exposing others while infectious. 

Furthermore, CDC continues to 

recommend that people wear masks in 

indoor public transportation settings. 

Applicability of the Paperwork 

Reduction Act 

In accordance with this Rescission 

Order, the Passenger Disclosure and 

Attestation form (OMB Control No. 

0920–1318) has been amended to 

remove the testing requirement. CDC 

will publish a separate notice regarding 

this change under the Paperwork 

Reduction Act. 

Referenced Order 

A copy of the Order is provided 

below, and a copy of the signed Order 

can be found at https://www.cdc.gov/ 

quarantine/pdf/rescission-globaltesting-order-p.pdf.pdf. 

Centers for Disease Control and 

Prevention Department of Health and 

Human Services 

Order Under Section 361 of the Public 

Health Service Act (42 U.S.C. 264) and 

42 Code of Federal Regulations 71.20, 

71.31(B) 

Rescinding Requirement for Negative 

Pre-Departure Covid–19 Test Result or 

Documentation of Recovery From 

Covid–19 for All Airline or Other 

Aircraft Passengers Arriving Into the 

United States From Any Foreign 

Country 

Summary and Action 

On January 26, 2021, the Centers for 

Disease Control and Prevention (CDC), 

located within the Department of Health 

and Human Services (HHS), issued an 

Order titled, ‘‘Requirement for Negative 

Pre-Departure COVID–19 Test Result or 

Documentation of Recovery from 

COVID–19 for All Airline or Other 

Aircraft Passengers Arriving Into the 

United States From Any Foreign 

Country.’’ 86 FR 7387 (Jan. 28, 2021). As 

subsequently amended, the Order 

currently requires all air passengers, 2 

years or older, traveling to the United 

States from a foreign country to present 

a negative COVID–19 test result from a 

sample taken no more than one day 

before departure, or documentation of 

recovery from COVID–19 in the past 90 

days, before boarding a flight. 86 FR 

69256 (Dec. 7, 2021).1

The Order was one of several actions 

taken by the Federal government during 

earlier phases of the COVID–19 

pandemic to help mitigate the further 

transmission and spread of SARS–CoV– 

2 variants into and within the United 

States. At that time, CDC concluded that 

it was a reasonable and necessary 

measure in light of the increased risk of 

transmission and spread of SARS–CoV– 

2 variants by international air travel into 

the United States, as well as the low rate 

of vaccination and infection-induced 

immunity in the United States, and 

emergence of new variants of concern. 

Indeed, when the Order was last 

amended, it identified the Omicron 

variant as a variant of concern, noting 

uncertainty about how easily that 

variant might spread, the severity of 

disease it might cause, and the level of 

protection against it that vaccines might 

afford. 86 FR at 69259–60. 

Since then, many circumstances have 

changed, including the widespread 

uptake of effective COVID–19 vaccines 

and accompanying vaccine- and 

infection-induced immunity, as well as 

the availability of effective therapeutics. 

However, CDC remains focused on 

preventing medically significant 

disease, hospitalizations, and deaths 

from COVID–19. CDC has determined 

that it is not currently necessary to leave 

the Order in place to prevent 

introduction of currently circulating 

SARS–CoV–2 variants into the United 

States. In its place, CDC has determined 

that travelers have access to tools (e.g., 

vaccines, therapeutics, and 

recommended prevention measures) 

and guidance that allow travelers to 

make informed choices about the use of 

pre-departure testing and other 

prevention measures. CDC continues to 

recommend that all travelers remain up 

to date with vaccination against COVID– 

19 and get tested for current infection 

with a viral test before and after they 

travel, and after any known exposure to 

a person with COVID–19, so they can 

take appropriate precautions to reduce 

the risk of exposing others while 

infectious. 

CDC monitors circulating SARS–CoV– 

2 variants around the world and can 

enhance prevention measures, including 

reinstituting testing requirements, as 

warranted, including if a variant 

emerges that may present increased risk 

of severe illness and death. Removing 

this requirement is consistent with the 

framework CDC released in February 

2022, ‘‘COVID–19 Community Levels,’’ 

reflecting public health’s focus on 

reducing medically significant disease, 

hospitalization, and deaths.2


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 115 / Wednesday, June 15, 2022 / Notices 36131 

3COVID–19 Vaccines Work, Centers for Disease 

Control and Prevention, https://www.cdc.gov/ 

coronavirus/2019-ncov/vaccines/effectiveness/ 

work.html (updated Dec. 23, 2021). See also 

Thompson MG, Natarajan K, Irving SA, et al. 

Effectiveness of a Third Dose of mRNA Vaccines 

Against COVID–19–Associated Emergency 

Department and Urgent Care Encounters and 

Hospitalizations Among Adults During Periods of 

Delta and Omicron Variant Predominance—VISION 

Network, 10 States, August 2021–January 2022. 

MMWR Morb Mortal Wkly Rep 2022;71:139–145 

(Jan. 28, 2022). DOI: http://dx.doi.org/10.15585/ 

mmwr.mm7104e3 (attributing decline of vaccine 

effectiveness to waning vaccine-induced immunity 

over time, possible increased immune evasion by 

SARS–CoV–2 variants, or a combination of these 

and other factors and finding that receiving a 

booster shot was highly effective at preventing 

COVID–19-associated emergency department and 

urgent care encounters and preventing COVID–19- 

associated hospitalizations). 

4COVID Data Tracker, Centers for Disease 

Control and Prevention, https://covid.cdc.gov/ 

covid-data-tracker/#vaccinations_vacc-peopleonedose-pop-5yr (last visited June 10, 2022). 

5COVID Data Tracker Weekly Review: The Time 

Is Now—Interpretive Summary for June 3, 2022, 

Centers for Disease Control and Prevention, https:// 

www.cdc.gov/coronavirus/2019-ncov/covid-data/ 

covidview/index.html (June 3, 2022). 

6COVID–19 Vaccine Boosters, Centers for Disease 

Control and Prevention, https://www.cdc.gov/ 

coronavirus/2019-ncov/vaccines/boostershot.html#second-booster (updated May 24, 2022). 

7National COVID–19 Preparedness Plan—March 

2022, https://www.whitehouse.gov/wp-content/ 

uploads/2022/03/NAT-COVID-19-PREPAREDNESSPLAN.pdf (last visited Mar. 30, 2022). Antiviral 

pills will also be added to the stockpile for the first 

time. See also Information About COVID–19 EUAs 

for Medical Devices, U.S. Food and Drug 

Administration, https://www.fda.gov/emergencypreparedness-and-response/mcm-legal-regulatoryand-policy-framework/emergency-useauthorization#coviddrugs (updated June 3, 2022); 

FDA News Release: Coronavirus (COVID–19) 

Update: FDA Authorizes First Oral Antiviral for 

Treatment of COVID–19, U.S. Food and Drug 

Administration, https://www.fda.gov/news-events/ 

press-announcements/coronavirus-covid-19- 

update-fda-authorizes-first-oral-antiviral-treatmentcovid-19 (Dec. 22, 2021). 

8Science Brief: Indicators for Monitoring COVID– 

19 Community Levels and Making Public Health 

Recommendations, Centers for Disease Control and 

Prevention, https://www.cdc.gov/coronavirus/2019- 

ncov/science/science-briefs/indicators-monitoringcommunity-levels.html (updated Mar. 4, 2022); 

Nationwide COVID–19 Infection- and VaccinationInduced Antibody Seroprevalence (Blood 

donations), Centers for Disease Control and 

Prevention, https://covid.cdc.gov/covid-datatracker/#nationwide-blood-donor-seroprevalence 

(last updated Feb. 18, 2022). 

9This Order is not a legislative rule within the 

meaning of the Administrative Procedure Act 

(‘‘APA’’) but rather a rescission of a previous Order 

undertaken as an emergency action under the 

existing authority of 42 U.S.C. 264(a) and 42 CFR 

71.20, 71.31(b), which was taken without notice 

and comment. In the event that a court determines 

this rescission qualifies as a legislative rule under 

the APA, notice and comment and a delay in 

effective date are not required because the prior 

Order was established without notice and comment 

and there is good cause to lift that restriction 

immediately, given the current judgment that it is 

unnecessary to prevent the introduction of COVID– 

19 into the United States and to seek comment prior 

to the effective date of this notice would be 

impracticable and contrary to the public interest. 5 

U.S.C. 553(b)(3)(B). Further, while this Order is 

major under the Congressional Review Act ‘‘CRA’’, 

it is not necessary to delay the effective date for 

similar reasons of good cause. 5 U.S.C. 808(2). 

Vaccines, including boosters, 

continue to be the most important 

public health tool for fighting COVID– 

19, and CDC recommends that all 

people get vaccinated against COVID–19 

as soon as they are eligible and stay up 

to date with their vaccinations.3 When 

the Order was first issued in January 

2021, the United States and countries 

around the world were just embarking 

on efforts to vaccinate their populations 

and learn about emerging variants. Now, 

as of June 9, 2022, 70.9% of the U.S. 

population five years of age and older 

has received a primary series.4

Additionally, booster shots are 

recommended for and available to 

individuals five years of age and older; 5

second booster shots are now 

recommended for adults ages 50 years 

or older and people ages 12 years and 

older who are moderately or severely 

immunocompromised.6 The increased 

percentage of individuals who are not 

only fully vaccinated with a primary 

series but have also received one or 

more booster doses strengthens 

community and individual protection 

against serious illness from SARS–CoV– 

2 and reduces the associated strain on 

healthcare infrastructure. We know that 

the now-dominant Omicron variant, 

though more transmissible than prior 

variants, has generally caused less 

severe disease among those who are 

infected. COVID–19 vaccination still 

remains an effective measure to prevent 

medically significant disease, 

hospitalizations, and deaths. 

Similarly, the availability of 

efficacious and accessible treatments 

adds a powerful layer of protection 

against severe COVID–19 that was not 

available in January 2021.7 The U.S. 

Government’s commitment to making 

such medications available and the 

ability to produce variant-specific 

treatments are critical components of 

the next phase of the fight against 

COVID–19. The observed reduction in 

severity of COVID–19 cases and ongoing 

effective use of pharmaceutical 

interventions contribute greatly to 

minimize medically significant disease 

and largely prevent excessive strain on 

the healthcare sector at this stage in the 

pandemic.8

Therefore, based on these 

considerations, I have concluded that 

continuation of the Order is not 

currently necessary.9 There being no 

operational need to delay 

implementation of this rescission for 

more than a short period of time, it shall 

take effect for all aircraft departing from 

their point of origin on or after Sunday, 

June 12, 2022, at 12:01 a.m. Eastern 

Daylight Time (EDT). Importantly, CDC 

continues to recommend that all 

travelers remain up to date with 

vaccination against COVID–19 and get 

tested for current infection with a viral 

test before and after they travel, and 

after any known exposure to a person 

with COVID–19, so they can take 

appropriate precautions to reduce the 

risk of transmission while infectious. 

Furthermore, CDC continues to 

recommend that people wear masks in 

indoor public transportation settings. 

Effective Date 

This rescission shall be effective for 

all aircraft departing their point of 

origin on or after June 12, 2022, at 12:01 

a.m. EDT. 

Sherri Berger, 

Chief of Staff, Centers for Disease Control 

and Prevention. 

[FR Doc. 2022–13022 Filed 6–13–22; 4:15 pm] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Single-Source 

Cooperative Agreement To Fund 

Ministry of Health (MOH)—Trinidad & 

Tobago (TT) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

award of approximately $2,000,000 for 

Year 1 of funding to the Ministry of 

Health– Trinidad & Tobago. This award 

will help build national capacity of TT 

to treat HIV and other diseases of public 

health importance impacting people 

living with HIV (PLHIV) and 

populations affected by HIV, as well as 

move progress towards achieving the 

95–95–95 goals and ensure sustainable 

control of the epidemic in TT. Funding 

amounts for years 2–5 will be set at 

continuation. 

DATES: The period for this award will be 

September 30, 2022, through September 

29, 2027. 

FOR FURTHER INFORMATION CONTACT: 

Douan Kirivong, Center for Global 

Health, Centers for Disease Control and 

Prevention, 142 Old Hope Road, 


jspears on DSK121TN23PROD with NOTICES1